EGFR and non-small cell lung carcinoma: Targeted cancer therapies have produced significant clinical responses in NSCLC patients; for example, epidermal growth factor receptor tyrosine kinase inhibitors (erlotinib, gefitinib, and osimertinib) have been successfully used for NSCLC patients with EGFR mutation [3,4,5,6].